{"id":"https://openalex.org/W2030331663","doi":"https://doi.org/10.1097/ico.0b013e3182a7f3bf","title":"Self-Assembling Colloidal System for the Ocular Administration of Cyclosporine A","display_name":"Self-Assembling Colloidal System for the Ocular Administration of Cyclosporine A","alternate_titles":[],"publication_year":2013,"publication_date":"2013-10-25","ids":{"openalex":"https://openalex.org/W2030331663","doi":"https://doi.org/10.1097/ico.0b013e3182a7f3bf","mag":"2030331663","pmid":"https://pubmed.ncbi.nlm.nih.gov/24162754"},"language":"en","primary_location":{"id":"doi:10.1097/ico.0b013e3182a7f3bf","doi":"https://doi.org/10.1097/ico.0b013e3182a7f3bf","is_oa":false,"landing_page_url":"https://doi.org/10.1097/ico.0b013e3182a7f3bf","pdf_url":null,"source":{"id":"https://openalex.org/S145806103","display_name":"Cornea","issn_l":"0277-3740","issn":["0277-3740","1536-4798"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cornea","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2030331663"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5070973161","display_name":"Christoph Luschmann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I25974101","display_name":"University of W\u00fcrzburg","ror":"https://ror.org/00fbnyb24","country_code":"DE","type":"education","lineage":["https://openalex.org/I25974101"]},{"id":"https://openalex.org/I3129555431","display_name":"University Hospital Regensburg","ror":"https://ror.org/01226dv09","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I3129555431"]},{"id":"https://openalex.org/I4210126310","display_name":"Universit\u00e4tsklinikum W\u00fcrzburg","ror":"https://ror.org/03pvr2g57","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210126310"]},{"id":"https://openalex.org/I4210154971","display_name":"Pharma Stulln (Germany)","ror":"https://ror.org/04rgxfp73","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210154971"]},{"id":"https://openalex.org/I60668342","display_name":"University of Regensburg","ror":"https://ror.org/01eezs655","country_code":"DE","type":"education","lineage":["https://openalex.org/I60668342"]},{"id":"https://openalex.org/I7877124","display_name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","ror":"https://ror.org/001w7jn25","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I7877124"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Christoph Luschmann","raw_affiliation_strings":["*Department of Pharmaceutical Technology, University of Regensburg, Regensburg, Germany; \u2020Department for Functional Materials in Medicine and Dentistry, University of Wuerzburg, Wuerzburg, Germany; \u2021Department of Experimental Ophthalmology, University Hospital Regensburg, Regensburg, Germany; \u00a7Experimental Ophthalmology, Department Ophthalmology, Charit\u00e9 University Medicine Berlin, Berlin, Germany; and \u00b6Pharma Stulln GmbH, Stulln, Germany","*Department of Pharmaceutical Technology, University of Regensburg, Regensburg, Germany","Accepted August 02, 2013","K. Luschmann is the director of Pharma Stulln GmbH. The other authors have no other funding or conflicts of interest to disclose","Received June 05, 2013","Reprints: Achim Goepferich, Department of Pharmaceutical Technology, University of Regensburg, Regensburg 93040, Germany (e-mail: [email\u00a0protected])","Supported by Bavarian Research Foundation (BFS AZ 870-90)","\u00a7Experimental Ophthalmology, Department Ophthalmology, Charit\u00e9 University Medicine Berlin, Berlin, Germany","\u00b6Pharma Stulln GmbH, Stulln, Germany","\u2020Department for Functional Materials in Medicine and Dentistry, University of Wuerzburg, Wuerzburg, Germany","\u2021Department of Experimental Ophthalmology, University Hospital Regensburg, Regensburg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"*Department of Pharmaceutical Technology, University of Regensburg, Regensburg, Germany; \u2020Department for Functional Materials in Medicine and Dentistry, University of Wuerzburg, Wuerzburg, Germany; \u2021Department of Experimental Ophthalmology, University Hospital Regensburg, Regensburg, Germany; \u00a7Experimental Ophthalmology, Department Ophthalmology, Charit\u00e9 University Medicine Berlin, Berlin, Germany; and \u00b6Pharma Stulln GmbH, Stulln, Germany","institution_ids":["https://openalex.org/I25974101","https://openalex.org/I3129555431","https://openalex.org/I4210126310","https://openalex.org/I4210154971","https://openalex.org/I60668342","https://openalex.org/I7877124"]},{"raw_affiliation_string":"*Department of Pharmaceutical Technology, University of Regensburg, Regensburg, Germany","institution_ids":["https://openalex.org/I60668342"]},{"raw_affiliation_string":"Accepted August 02, 2013","institution_ids":[]},{"raw_affiliation_string":"K. Luschmann is the director of Pharma Stulln GmbH. The other authors have no other funding or conflicts of interest to disclose","institution_ids":["https://openalex.org/I4210154971"]},{"raw_affiliation_string":"Received June 05, 2013","institution_ids":[]},{"raw_affiliation_string":"Reprints: Achim Goepferich, Department of Pharmaceutical Technology, University of Regensburg, Regensburg 93040, Germany (e-mail: [email\u00a0protected])","institution_ids":["https://openalex.org/I60668342"]},{"raw_affiliation_string":"Supported by Bavarian Research Foundation (BFS AZ 870-90)","institution_ids":[]},{"raw_affiliation_string":"\u00a7Experimental Ophthalmology, Department Ophthalmology, Charit\u00e9 University Medicine Berlin, Berlin, Germany","institution_ids":["https://openalex.org/I7877124"]},{"raw_affiliation_string":"\u00b6Pharma Stulln GmbH, Stulln, Germany","institution_ids":["https://openalex.org/I4210154971"]},{"raw_affiliation_string":"\u2020Department for Functional Materials in Medicine and Dentistry, University of Wuerzburg, Wuerzburg, Germany","institution_ids":["https://openalex.org/I25974101"]},{"raw_affiliation_string":"\u2021Department of Experimental Ophthalmology, University Hospital Regensburg, Regensburg, Germany","institution_ids":["https://openalex.org/I3129555431"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035548610","display_name":"J\u00f6rg Te\u00dfmar","orcid":"https://orcid.org/0000-0001-7057-5369","observed_orcids":["https://orcid.org/0000-0001-7057-5369"]},"institutions":[{"id":"https://openalex.org/I25974101","display_name":"University of W\u00fcrzburg","ror":"https://ror.org/00fbnyb24","country_code":"DE","type":"education","lineage":["https://openalex.org/I25974101"]},{"id":"https://openalex.org/I3129555431","display_name":"University Hospital Regensburg","ror":"https://ror.org/01226dv09","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I3129555431"]},{"id":"https://openalex.org/I4210154971","display_name":"Pharma Stulln (Germany)","ror":"https://ror.org/04rgxfp73","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210154971"]},{"id":"https://openalex.org/I60668342","display_name":"University of Regensburg","ror":"https://ror.org/01eezs655","country_code":"DE","type":"education","lineage":["https://openalex.org/I60668342"]},{"id":"https://openalex.org/I7877124","display_name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","ror":"https://ror.org/001w7jn25","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I7877124"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Joerg Tessmar","raw_affiliation_strings":["*Department of Pharmaceutical Technology, University of Regensburg, Regensburg, Germany","Accepted August 02, 2013","K. Luschmann is the director of Pharma Stulln GmbH. The other authors have no other funding or conflicts of interest to disclose","Received June 05, 2013","Reprints: Achim Goepferich, Department of Pharmaceutical Technology, University of Regensburg, Regensburg 93040, Germany (e-mail: [email\u00a0protected])","Supported by Bavarian Research Foundation (BFS AZ 870-90)","\u00a7Experimental Ophthalmology, Department Ophthalmology, Charit\u00e9 University Medicine Berlin, Berlin, Germany","\u00b6Pharma Stulln GmbH, Stulln, Germany","\u2020Department for Functional Materials in Medicine and Dentistry, University of Wuerzburg, Wuerzburg, Germany","\u2021Department of Experimental Ophthalmology, University Hospital Regensburg, Regensburg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"*Department of Pharmaceutical Technology, University of Regensburg, Regensburg, Germany","institution_ids":["https://openalex.org/I60668342"]},{"raw_affiliation_string":"Accepted August 02, 2013","institution_ids":[]},{"raw_affiliation_string":"K. Luschmann is the director of Pharma Stulln GmbH. The other authors have no other funding or conflicts of interest to disclose","institution_ids":["https://openalex.org/I4210154971"]},{"raw_affiliation_string":"Received June 05, 2013","institution_ids":[]},{"raw_affiliation_string":"Reprints: Achim Goepferich, Department of Pharmaceutical Technology, University of Regensburg, Regensburg 93040, Germany (e-mail: [email\u00a0protected])","institution_ids":["https://openalex.org/I60668342"]},{"raw_affiliation_string":"Supported by Bavarian Research Foundation (BFS AZ 870-90)","institution_ids":[]},{"raw_affiliation_string":"\u00a7Experimental Ophthalmology, Department Ophthalmology, Charit\u00e9 University Medicine Berlin, Berlin, Germany","institution_ids":["https://openalex.org/I7877124"]},{"raw_affiliation_string":"\u00b6Pharma Stulln GmbH, Stulln, Germany","institution_ids":["https://openalex.org/I4210154971"]},{"raw_affiliation_string":"\u2020Department for Functional Materials in Medicine and Dentistry, University of Wuerzburg, Wuerzburg, Germany","institution_ids":["https://openalex.org/I25974101"]},{"raw_affiliation_string":"\u2021Department of Experimental Ophthalmology, University Hospital Regensburg, Regensburg, Germany","institution_ids":["https://openalex.org/I3129555431"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009040749","display_name":"Simon Schoeberl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I25974101","display_name":"University of W\u00fcrzburg","ror":"https://ror.org/00fbnyb24","country_code":"DE","type":"education","lineage":["https://openalex.org/I25974101"]},{"id":"https://openalex.org/I3129555431","display_name":"University Hospital Regensburg","ror":"https://ror.org/01226dv09","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I3129555431"]},{"id":"https://openalex.org/I4210154971","display_name":"Pharma Stulln (Germany)","ror":"https://ror.org/04rgxfp73","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210154971"]},{"id":"https://openalex.org/I60668342","display_name":"University of Regensburg","ror":"https://ror.org/01eezs655","country_code":"DE","type":"education","lineage":["https://openalex.org/I60668342"]},{"id":"https://openalex.org/I7877124","display_name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","ror":"https://ror.org/001w7jn25","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I7877124"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Simon Schoeberl","raw_affiliation_strings":["*Department of Pharmaceutical Technology, University of Regensburg, Regensburg, Germany","Accepted August 02, 2013","K. Luschmann is the director of Pharma Stulln GmbH. The other authors have no other funding or conflicts of interest to disclose","Received June 05, 2013","Reprints: Achim Goepferich, Department of Pharmaceutical Technology, University of Regensburg, Regensburg 93040, Germany (e-mail: [email\u00a0protected])","Supported by Bavarian Research Foundation (BFS AZ 870-90)","\u00a7Experimental Ophthalmology, Department Ophthalmology, Charit\u00e9 University Medicine Berlin, Berlin, Germany","\u00b6Pharma Stulln GmbH, Stulln, Germany","\u2020Department for Functional Materials in Medicine and Dentistry, University of Wuerzburg, Wuerzburg, Germany","\u2021Department of Experimental Ophthalmology, University Hospital Regensburg, Regensburg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"*Department of Pharmaceutical Technology, University of Regensburg, Regensburg, Germany","institution_ids":["https://openalex.org/I60668342"]},{"raw_affiliation_string":"Accepted August 02, 2013","institution_ids":[]},{"raw_affiliation_string":"K. Luschmann is the director of Pharma Stulln GmbH. The other authors have no other funding or conflicts of interest to disclose","institution_ids":["https://openalex.org/I4210154971"]},{"raw_affiliation_string":"Received June 05, 2013","institution_ids":[]},{"raw_affiliation_string":"Reprints: Achim Goepferich, Department of Pharmaceutical Technology, University of Regensburg, Regensburg 93040, Germany (e-mail: [email\u00a0protected])","institution_ids":["https://openalex.org/I60668342"]},{"raw_affiliation_string":"Supported by Bavarian Research Foundation (BFS AZ 870-90)","institution_ids":[]},{"raw_affiliation_string":"\u00a7Experimental Ophthalmology, Department Ophthalmology, Charit\u00e9 University Medicine Berlin, Berlin, Germany","institution_ids":["https://openalex.org/I7877124"]},{"raw_affiliation_string":"\u00b6Pharma Stulln GmbH, Stulln, Germany","institution_ids":["https://openalex.org/I4210154971"]},{"raw_affiliation_string":"\u2020Department for Functional Materials in Medicine and Dentistry, University of Wuerzburg, Wuerzburg, Germany","institution_ids":["https://openalex.org/I25974101"]},{"raw_affiliation_string":"\u2021Department of Experimental Ophthalmology, University Hospital Regensburg, Regensburg, Germany","institution_ids":["https://openalex.org/I3129555431"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020880864","display_name":"Olaf Strau\u00df","orcid":"https://orcid.org/0000-0002-6272-8596","observed_orcids":["https://orcid.org/0000-0002-6272-8596"]},"institutions":[{"id":"https://openalex.org/I25974101","display_name":"University of W\u00fcrzburg","ror":"https://ror.org/00fbnyb24","country_code":"DE","type":"education","lineage":["https://openalex.org/I25974101"]},{"id":"https://openalex.org/I3129555431","display_name":"University Hospital Regensburg","ror":"https://ror.org/01226dv09","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I3129555431"]},{"id":"https://openalex.org/I4210154971","display_name":"Pharma Stulln (Germany)","ror":"https://ror.org/04rgxfp73","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210154971"]},{"id":"https://openalex.org/I60668342","display_name":"University of Regensburg","ror":"https://ror.org/01eezs655","country_code":"DE","type":"education","lineage":["https://openalex.org/I60668342"]},{"id":"https://openalex.org/I7877124","display_name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","ror":"https://ror.org/001w7jn25","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I7877124"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Olaf Strau","raw_affiliation_strings":["*Department of Pharmaceutical Technology, University of Regensburg, Regensburg, Germany","Accepted August 02, 2013","K. Luschmann is the director of Pharma Stulln GmbH. The other authors have no other funding or conflicts of interest to disclose","Received June 05, 2013","Reprints: Achim Goepferich, Department of Pharmaceutical Technology, University of Regensburg, Regensburg 93040, Germany (e-mail: [email\u00a0protected])","Supported by Bavarian Research Foundation (BFS AZ 870-90)","\u00a7Experimental Ophthalmology, Department Ophthalmology, Charit\u00e9 University Medicine Berlin, Berlin, Germany","\u00b6Pharma Stulln GmbH, Stulln, Germany","\u2020Department for Functional Materials in Medicine and Dentistry, University of Wuerzburg, Wuerzburg, Germany","\u2021Department of Experimental Ophthalmology, University Hospital Regensburg, Regensburg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"*Department of Pharmaceutical Technology, University of Regensburg, Regensburg, Germany","institution_ids":["https://openalex.org/I60668342"]},{"raw_affiliation_string":"Accepted August 02, 2013","institution_ids":[]},{"raw_affiliation_string":"K. Luschmann is the director of Pharma Stulln GmbH. The other authors have no other funding or conflicts of interest to disclose","institution_ids":["https://openalex.org/I4210154971"]},{"raw_affiliation_string":"Received June 05, 2013","institution_ids":[]},{"raw_affiliation_string":"Reprints: Achim Goepferich, Department of Pharmaceutical Technology, University of Regensburg, Regensburg 93040, Germany (e-mail: [email\u00a0protected])","institution_ids":["https://openalex.org/I60668342"]},{"raw_affiliation_string":"Supported by Bavarian Research Foundation (BFS AZ 870-90)","institution_ids":[]},{"raw_affiliation_string":"\u00a7Experimental Ophthalmology, Department Ophthalmology, Charit\u00e9 University Medicine Berlin, Berlin, Germany","institution_ids":["https://openalex.org/I7877124"]},{"raw_affiliation_string":"\u00b6Pharma Stulln GmbH, Stulln, Germany","institution_ids":["https://openalex.org/I4210154971"]},{"raw_affiliation_string":"\u2020Department for Functional Materials in Medicine and Dentistry, University of Wuerzburg, Wuerzburg, Germany","institution_ids":["https://openalex.org/I25974101"]},{"raw_affiliation_string":"\u2021Department of Experimental Ophthalmology, University Hospital Regensburg, Regensburg, Germany","institution_ids":["https://openalex.org/I3129555431"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009751593","display_name":"Karl Luschmann","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I25974101","display_name":"University of W\u00fcrzburg","ror":"https://ror.org/00fbnyb24","country_code":"DE","type":"education","lineage":["https://openalex.org/I25974101"]},{"id":"https://openalex.org/I3129555431","display_name":"University Hospital Regensburg","ror":"https://ror.org/01226dv09","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I3129555431"]},{"id":"https://openalex.org/I4210154971","display_name":"Pharma Stulln (Germany)","ror":"https://ror.org/04rgxfp73","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210154971"]},{"id":"https://openalex.org/I60668342","display_name":"University of Regensburg","ror":"https://ror.org/01eezs655","country_code":"DE","type":"education","lineage":["https://openalex.org/I60668342"]},{"id":"https://openalex.org/I7877124","display_name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","ror":"https://ror.org/001w7jn25","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I7877124"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Karl Luschmann","raw_affiliation_strings":["*Department of Pharmaceutical Technology, University of Regensburg, Regensburg, Germany","Accepted August 02, 2013","K. Luschmann is the director of Pharma Stulln GmbH. The other authors have no other funding or conflicts of interest to disclose","Received June 05, 2013","Reprints: Achim Goepferich, Department of Pharmaceutical Technology, University of Regensburg, Regensburg 93040, Germany (e-mail: [email\u00a0protected])","Supported by Bavarian Research Foundation (BFS AZ 870-90)","\u00a7Experimental Ophthalmology, Department Ophthalmology, Charit\u00e9 University Medicine Berlin, Berlin, Germany","\u00b6Pharma Stulln GmbH, Stulln, Germany","\u2020Department for Functional Materials in Medicine and Dentistry, University of Wuerzburg, Wuerzburg, Germany","\u2021Department of Experimental Ophthalmology, University Hospital Regensburg, Regensburg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"*Department of Pharmaceutical Technology, University of Regensburg, Regensburg, Germany","institution_ids":["https://openalex.org/I60668342"]},{"raw_affiliation_string":"Accepted August 02, 2013","institution_ids":[]},{"raw_affiliation_string":"K. Luschmann is the director of Pharma Stulln GmbH. The other authors have no other funding or conflicts of interest to disclose","institution_ids":["https://openalex.org/I4210154971"]},{"raw_affiliation_string":"Received June 05, 2013","institution_ids":[]},{"raw_affiliation_string":"Reprints: Achim Goepferich, Department of Pharmaceutical Technology, University of Regensburg, Regensburg 93040, Germany (e-mail: [email\u00a0protected])","institution_ids":["https://openalex.org/I60668342"]},{"raw_affiliation_string":"Supported by Bavarian Research Foundation (BFS AZ 870-90)","institution_ids":[]},{"raw_affiliation_string":"\u00a7Experimental Ophthalmology, Department Ophthalmology, Charit\u00e9 University Medicine Berlin, Berlin, Germany","institution_ids":["https://openalex.org/I7877124"]},{"raw_affiliation_string":"\u00b6Pharma Stulln GmbH, Stulln, Germany","institution_ids":["https://openalex.org/I4210154971"]},{"raw_affiliation_string":"\u2020Department for Functional Materials in Medicine and Dentistry, University of Wuerzburg, Wuerzburg, Germany","institution_ids":["https://openalex.org/I25974101"]},{"raw_affiliation_string":"\u2021Department of Experimental Ophthalmology, University Hospital Regensburg, Regensburg, Germany","institution_ids":["https://openalex.org/I3129555431"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5024896167","display_name":"Achim M. G\u00f6pferich","orcid":"https://orcid.org/0000-0002-7646-0252","observed_orcids":["https://orcid.org/0000-0002-7646-0252","https://orcid.org/0000-0003-0190-7811"]},"institutions":[{"id":"https://openalex.org/I25974101","display_name":"University of W\u00fcrzburg","ror":"https://ror.org/00fbnyb24","country_code":"DE","type":"education","lineage":["https://openalex.org/I25974101"]},{"id":"https://openalex.org/I3129555431","display_name":"University Hospital Regensburg","ror":"https://ror.org/01226dv09","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I3129555431"]},{"id":"https://openalex.org/I4210154971","display_name":"Pharma Stulln (Germany)","ror":"https://ror.org/04rgxfp73","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210154971"]},{"id":"https://openalex.org/I60668342","display_name":"University of Regensburg","ror":"https://ror.org/01eezs655","country_code":"DE","type":"education","lineage":["https://openalex.org/I60668342"]},{"id":"https://openalex.org/I7877124","display_name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","ror":"https://ror.org/001w7jn25","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I7877124"]}],"countries":["DE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Achim Goepferich","raw_affiliation_strings":["*Department of Pharmaceutical Technology, University of Regensburg, Regensburg, Germany","Accepted August 02, 2013","K. Luschmann is the director of Pharma Stulln GmbH. The other authors have no other funding or conflicts of interest to disclose","Received June 05, 2013","Reprints: Achim Goepferich, Department of Pharmaceutical Technology, University of Regensburg, Regensburg 93040, Germany (e-mail: [email\u00a0protected])","Supported by Bavarian Research Foundation (BFS AZ 870-90)","\u00a7Experimental Ophthalmology, Department Ophthalmology, Charit\u00e9 University Medicine Berlin, Berlin, Germany","\u00b6Pharma Stulln GmbH, Stulln, Germany","\u2020Department for Functional Materials in Medicine and Dentistry, University of Wuerzburg, Wuerzburg, Germany","\u2021Department of Experimental Ophthalmology, University Hospital Regensburg, Regensburg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"*Department of Pharmaceutical Technology, University of Regensburg, Regensburg, Germany","institution_ids":["https://openalex.org/I60668342"]},{"raw_affiliation_string":"Accepted August 02, 2013","institution_ids":[]},{"raw_affiliation_string":"K. Luschmann is the director of Pharma Stulln GmbH. The other authors have no other funding or conflicts of interest to disclose","institution_ids":["https://openalex.org/I4210154971"]},{"raw_affiliation_string":"Received June 05, 2013","institution_ids":[]},{"raw_affiliation_string":"Reprints: Achim Goepferich, Department of Pharmaceutical Technology, University of Regensburg, Regensburg 93040, Germany (e-mail: [email\u00a0protected])","institution_ids":["https://openalex.org/I60668342"]},{"raw_affiliation_string":"Supported by Bavarian Research Foundation (BFS AZ 870-90)","institution_ids":[]},{"raw_affiliation_string":"\u00a7Experimental Ophthalmology, Department Ophthalmology, Charit\u00e9 University Medicine Berlin, Berlin, Germany","institution_ids":["https://openalex.org/I7877124"]},{"raw_affiliation_string":"\u00b6Pharma Stulln GmbH, Stulln, Germany","institution_ids":["https://openalex.org/I4210154971"]},{"raw_affiliation_string":"\u2020Department for Functional Materials in Medicine and Dentistry, University of Wuerzburg, Wuerzburg, Germany","institution_ids":["https://openalex.org/I25974101"]},{"raw_affiliation_string":"\u2021Department of Experimental Ophthalmology, University Hospital Regensburg, Regensburg, Germany","institution_ids":["https://openalex.org/I3129555431"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5024896167"],"corresponding_institution_ids":["https://openalex.org/I25974101","https://openalex.org/I3129555431","https://openalex.org/I4210154971","https://openalex.org/I60668342","https://openalex.org/I7877124"],"apc_list":null,"apc_paid":null,"fwci":1.8884,"has_fulltext":false,"cited_by_count":31,"citation_normalized_percentile":{"value":0.80656371,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"33","issue":"1","first_page":"77","last_page":"81"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10920","display_name":"Advanced Drug Delivery Systems","score":0.9907000064849854,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10997","display_name":"Ocular Surface and Contact Lens","score":0.003800000064074993,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10721","display_name":"Surfactants and Colloidal Systems","score":0.003000000026077032,"subfield":{"id":"https://openalex.org/subfields/1606","display_name":"Physical and Theoretical Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cyclosporine","display_name":"cyclosporine","score":1.0},{"id":"https://openalex.org/keywords/ocular-drug-delivery","display_name":"ocular drug delivery","score":0.8190000057220459},{"id":"https://openalex.org/keywords/self-assembling-micelles","display_name":"self-assembling micelles","score":0.8650000095367432},{"id":"https://openalex.org/keywords/encapsulation-efficiency","display_name":"encapsulation efficiency","score":0.7379999756813049},{"id":"https://openalex.org/keywords/porcine-eye-model","display_name":"porcine eye model","score":0.8320000171661377},{"id":"https://openalex.org/keywords/restasis","display_name":"Restasis","score":0.6589999794960022}],"concepts":[{"id":"https://openalex.org/C2777516009","wikidata":"https://www.wikidata.org/wiki/Q194207","display_name":"Ethylene glycol","level":2,"score":0.7315115332603455},{"id":"https://openalex.org/C184651966","wikidata":"https://www.wikidata.org/wiki/Q906356","display_name":"Aqueous solution","level":2,"score":0.6887438297271729},{"id":"https://openalex.org/C2776882836","wikidata":"https://www.wikidata.org/wiki/Q168291","display_name":"Cornea","level":2,"score":0.6776450872421265},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.632289707660675},{"id":"https://openalex.org/C11268172","wikidata":"https://www.wikidata.org/wiki/Q421110","display_name":"Micelle","level":3,"score":0.6129664182662964},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5757643580436707},{"id":"https://openalex.org/C58226133","wikidata":"https://www.wikidata.org/wiki/Q1324199","display_name":"Pulmonary surfactant","level":2,"score":0.4874758720397949},{"id":"https://openalex.org/C43617362","wikidata":"https://www.wikidata.org/wiki/Q170050","display_name":"Chromatography","level":1,"score":0.4265033006668091},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2679203748703003},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.22597774863243103},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.16947713494300842},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.1343068778514862},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.13271880149841309}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003102","descriptor_name":"Colloids","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003315","descriptor_name":"Cornea","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D004337","descriptor_name":"Drug Carriers","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D004337","descriptor_name":"Drug Carriers","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D008823","descriptor_name":"Micelles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009883","descriptor_name":"Ophthalmic Solutions","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009883","descriptor_name":"Ophthalmic Solutions","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D012995","descriptor_name":"Solubility","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013501","descriptor_name":"Surface-Active Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013501","descriptor_name":"Surface-Active Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D013552","descriptor_name":"Swine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016503","descriptor_name":"Drug Delivery Systems","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D016572","descriptor_name":"Cyclosporine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D016572","descriptor_name":"Cyclosporine","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D016572","descriptor_name":"Cyclosporine","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D023421","descriptor_name":"Models, Animal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060433","descriptor_name":"Administration, Ophthalmic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1097/ico.0b013e3182a7f3bf","doi":"https://doi.org/10.1097/ico.0b013e3182a7f3bf","is_oa":false,"landing_page_url":"https://doi.org/10.1097/ico.0b013e3182a7f3bf","pdf_url":null,"source":{"id":"https://openalex.org/S145806103","display_name":"Cornea","issn_l":"0277-3740","issn":["0277-3740","1536-4798"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cornea","raw_type":"journal-article"},{"id":"pmid:24162754","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24162754","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cornea","raw_type":"Journal Article"},{"id":"pmh:oai:epub.uni-regensburg.de:29289","doi":null,"is_oa":false,"landing_page_url":"https://epub.uni-regensburg.de/29289/","pdf_url":null,"source":{"id":"https://openalex.org/S4306401229","display_name":"University of Regensburg Publication Server (University of Regensburg)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I60668342","host_organization_name":"University of Regensburg","host_organization_lineage":["https://openalex.org/I60668342"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320321450","display_name":"Bayerische Forschungsstiftung","ror":"https://ror.org/00emnts94"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W13787203","https://openalex.org/W138624324","https://openalex.org/W187131593","https://openalex.org/W1550485225","https://openalex.org/W1979425595","https://openalex.org/W1987369876","https://openalex.org/W2003310190","https://openalex.org/W2005907688","https://openalex.org/W2013834122","https://openalex.org/W2028837722","https://openalex.org/W2040865586","https://openalex.org/W2051127111","https://openalex.org/W2055879989","https://openalex.org/W2056795722","https://openalex.org/W2065272974","https://openalex.org/W2065770204","https://openalex.org/W2069241556","https://openalex.org/W2086360721","https://openalex.org/W2087412677","https://openalex.org/W2089839511","https://openalex.org/W2121159328","https://openalex.org/W2135496837","https://openalex.org/W2171380936","https://openalex.org/W2414144137"],"related_works":["https://openalex.org/W1492593588","https://openalex.org/W1987369876","https://openalex.org/W2030579419","https://openalex.org/W7100177032","https://openalex.org/W2012245891","https://openalex.org/W2089839511","https://openalex.org/W3126182284","https://openalex.org/W2797901882","https://openalex.org/W311930526","https://openalex.org/W2056795722"],"abstract_inverted_index":{"PURPOSE:":[0],"In":[1,54,124,170],"this":[2],"study,":[3,61],"we":[4,172],"developed":[5],"a":[6,78,94,175],"self-assembling":[7],"micellar":[8,141],"system":[9],"to":[10,19,98,114,190,193],"deliver":[11],"cyclosporine":[12],"A":[13,74,103],"(CsA)":[14],"in":[15,40,56,68,101,127,134,186],"an":[16,55,69,187],"aqueous":[17,188],"solution":[18,83,143,164,189],"the":[20,27,62,125,135,140,161,182,191],"cornea.":[21],"METHODS:":[22],"Two":[23],"nonionic":[24],"surfactants":[25,89],"of":[26,42,96,118,154,184],"poly(ethylene":[28],"glycol)-fatty":[29],"alcohol":[30],"ether":[31],"type":[32],"(Sympatens":[33],"AS":[34,111],"and":[35,46,48,77,178],"Sympatens":[36,110],"ACS)":[37],"were":[38,66,137,149],"characterized":[39],"terms":[41],"micelle":[43],"size,":[44],"shape,":[45],"charge,":[47],"their":[49],"encapsulation":[50],"efficiency":[51],"for":[52,139,181],"CsA.":[53,123],"situ":[57,128],"single":[58],"dose":[59],"bioavailability":[60],"corneal":[63,196],"CsA":[64,80,142,185],"levels":[65,117,133],"determined":[67],"enucleated":[70],"porcine":[71,126],"eye":[72],"model.":[73],"commercial":[75],"formulation":[76],"2%":[79],"olive":[81,162],"oil":[82,163],"served":[84],"as":[85,105,107],"references.":[86],"RESULTS:":[87],"Both":[88],"formed":[90],"spherical":[91],"micelles":[92],"with":[93],"size":[95],"9":[97],"12":[99],"nm":[100],"water.":[102],"concentration":[104],"low":[106],"0.3%":[108],"(wt/vol)":[109,122],"was":[112],"sufficient":[113],"entrap":[115],"therapeutic":[116],"at":[119],"least":[120],"0.1%":[121],"model,":[129],"exceptionally":[130],"high":[131],"drug":[132],"cornea":[136,192],"obtained":[138],"(1557":[144],"\u00b1":[145,157,166],"407":[146],"ngCsA/gcornea).":[147,168],"They":[148],"significantly":[150],"higher":[151],"than":[152],"those":[153],"Restasis":[155],"(545":[156],"137":[158],"ngCsA/gcornea)":[159],"or":[160],"(452":[165],"142":[167],"CONCLUSIONS:":[169],"conclusion,":[171],"have":[173],"shown":[174],"promising":[176],"simple":[177],"efficient":[179],"approach":[180],"application":[183],"treat":[194],"inflammatory":[195],"diseases.":[197]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2030331663","counts_by_year":[{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
